Results 1 to 10 of about 36,254 (205)

Rivaroxaban as Secondary Thromboprophylaxis in Pediatric Patients With Short Bowel Syndrome. [PDF]

Case Rep Hematol
Journell AF, Peters CE, Meznarich J, Goteti S.   +3 more
europepmc   +1 more source

Spontaneous Perigastric Hematoma and Hemoperitoneum Associated With Rivaroxaban Therapy: A Case Report and Review of the Literature. [PDF]

Cureus
Rachad B, Mbina Nzienghi D, Chouaib N, Belkouch A.   +3 more
europepmc   +1 more source

Suzetrigine Is Not Expected to Have Clinically Relevant DDIs with Apixaban and Rivaroxaban Based on PBPK Modeling. [PDF]

J Clin Pharmacol
Wang G, Lakota E, Feng B, Jiang L, Liang G, Hare B.   +5 more
europepmc   +1 more source

Beyond the class effect: Rethinking anticoagulation in liver disease. [PDF]

JHEP Rep
Senzolo M, Hernandez-Gea V.
europepmc   +1 more source

Rivaroxaban suppresses factor Xa-Driven PAR-2-ERK inflammatory, catabolic, osteoclastogenic, and mitochondrial dysfunction signaling in osteoarthritis-relevant chondrocytes: a drug-repurposing strategy for joint inflammation. [PDF]

Front Pharmacol
Patnaik R, Jannati S, Kellett CF, Hing CB, Banerjee Y.   +4 more
europepmc   +1 more source

Libman-Sacks Endocarditis in Triple-Positive Antiphospholipid Syndrome Following Switch from Warfarin to Rivaroxaban: Improvement After Reinstitution of Warfarin and Escalation of Immunosuppression. [PDF]

Eur J Rheumatol
Saleh I, Salman S, Alkady A, Al-Saqabi F.   +3 more
europepmc   +1 more source

External Validation and Bayesian Forecasting of Rivaroxaban Population Pharmacokinetic Models in Older Chinese Patients with Nonvalvular Atrial Fibrillation. [PDF]

Drug Des Devel Ther
Chen J, Huang W, Chen G, Ge B, Zhao Q, Wang H, Ye J, Pan J, Mao K.   +8 more
europepmc   +1 more source

CytoSorb Application for Successful Control of Life-Threatening Gastrointestinal Bleeding Following Rivaroxaban Administration. [PDF]

Am J Case Rep
Raeva L, Petrov M, Cholakov M, Taha A, Petrov A, Handzhiev S.   +5 more
europepmc   +1 more source

Real-World Bleeding Outcomes Among Hospitalized Patients Receiving Apixaban or Rivaroxaban: A Single-Center Retrospective Cohort Study. [PDF]

Pharmaceuticals (Basel)
O'Rear C, Chapa-Rodriguez A, Singh A, Afzal S, Acharya R, Wickham M, Younus U.   +6 more
europepmc   +1 more source

Patient Self-Reported Global Satisfaction With Rivaroxaban in Patients With Atrial Fibrillation: A Comparison Between Oral Anticoagulation-Naïve Versus Oral Anticoagulation-Experienced Patients. [PDF]

Clin Cardiol
Markovic BG, Mihajlovic M, Kocijancic A, Simic J, Marinkovic M, Kovacevic V, Ivanisevic M, Isailovic N, Mujovic N, Pojskic B, Potpara T, GUARDIAN Investigators.   +11 more
europepmc   +1 more source